[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594542":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":50,"collaborators":53,"id":61,"slug":20,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":20,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[68Ga]Ga-DOTA-5G PET\u002FCT imaging","EXPERIMENTAL","Following an injection of up to 5 mCi of \\[68Ga\\]Ga DOTA-5G patients will be undergo PET\u002FCT scans.",[13],"Drug: [68Ga]Ga DOTA-5G",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","[68Ga]Ga DOTA-5G","Patients will be injected with up to 5 mCi of \\[68Ga\\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Julie Sutcliffe, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","916-734-5536","jlsutcliffe@ucdavis.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University of California Davis","RECRUITING","Sacramento","California","95817","United States",{"type":39,"coordinates":40},"Point",[41,42],-121.4944,38.58157,{"lat":42,"lon":41},[45,48],{"name":46,"role":27,"phone":47,"phoneExt":20,"email":29},"Julie L Sutcliffe","9167345536",{"name":49,"role":24,"phone":20,"phoneExt":20,"email":20},"Julie Sutcliffe",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Julie L. Sutcliffe, Ph.D","Professor",[54,57,59],{"name":55,"class":56},"Dr. Helen K Chew, University of California Davis","UNKNOWN",{"name":58,"class":56},"Dr. Cameron Foster, University of California Davis",{"name":60,"class":56},"Society of Nuclear Medicine and Molecular Imaging","100594542",false,"NCT07020806","[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic\u002FAdvanced Invasive Lobular Breast Cancer (LBC)","Inclusion Criteria:\n\n* (Ability to understand and willingness to sign a written informed consent document.\n* Men and women age ≥ 18 yrs\n* Confirmed presence of metastatic\u002Fadvanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST\n* Available archival tumor tissue\n* Eastern Cooperative Oncology Group Performance Status ≤ 2\n* Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells\u002Fmm3,Platelet count ≥ 100,000\u002Fmm3, Hemoglobin ≥ 8 g\u002FdL.\n* Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR \\>60 mL\u002Fmin\u002F1.73m\\*2\n* Anticipated life expectancy ≥ 3 months\n* Able to remain motionless for up to 30-60 minutes per scan.\n\nExclusion Criteria:\n\n* Pregnant and lactating women\n* Prisoners\n* Concurrent malignancy of a different histology that could confound imaging interpretation.\n* Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)","ALL","18 Years","89 Years",{"count":70,"type":71},30,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This is a prospective study using \\[68Ga\\]Ga DOTA-5G PET\u002FCT imaging in patients diagnosed with metastatic\u002Fadvanced invasive lobular breast cancer (LBC).",[77],"Metastatic Lobular Breast Carcinoma","2026-03-19",{"date":80,"type":81},"2026-03-23","ACTUAL",{"date":83,"type":81},"2025-11-18",{"date":85,"type":71},"2027-06",{"name":5,"class":6},1]